Effects of hormone receptor changes on endocrine therapy with breast cancer before and after neoadjuvant chemotherapy

VernacularTitle:乳腺癌新辅助化疗前后激素受体变化对术后内分泌治疗的影响
Author: Guanghua JIN ; Ying FAN ; Zihao LI
Keywords: Breast neoplasms; Endocrine therapy; Hormone receptor
From: Chinese Journal of Current Advances in General Surgery 2017;20(1):22-26
CountryChina
Language:Chinese
Abstract: Objective:To evaluate the impact of change in the hormone receptor (HR) status on the long-term outcomes of breast cancer patients treated with neoadjuvant chemotherapy (NAC).Methods:There were 215 patients for the HR status of their lesions before and after NAC.After surgery,59 cases were confirmed to have achieved complete remission of pathology,The expression of hormo ne receptors was not consistent in 63 patients before and after neoadjuvant chemotherapy.63 patients were divided into two groups,Group A:39 patients received standard endocrine therapy for 5 years after surgery and chemotherapy;Group B:24 patients were not treated with standard endocrine therapy after surgery and chemotherapy.Conclusions:The 3-year DFS rates were 77.4％ and 54.2％ in Group A and Group B patients,respectively,There was not statistical significancebetween the two groups.The 5-year overall survival rate for Group A patients was higher than that of Group B patients(74.3％ vs 45.8％,P=0.028),The difference was statistically significant.Conclusions:This study revealed that breast cancer patients with HR altered after NAC still benefit from standard endocrine therapy.